



Codes ATC: J04AK02 J04AC01 J04AB02

Indication	Tuberculosis	Code ICD11: 1B4Z
INN	Ethambutol + isoniazid + rifampicin	
Type de médicament	Chemical agent	
Type de liste	Liste de base	
Additional notes	WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.	
Formulations	Oral > Solid: 275 mg + 75 mg + 150 mg tablet	
Historique des statuts LME	Ajouté pour la première fois en 2007 (TRS 946) Modifié en 2007 (TRS 950)	
Sexe	Tous	
Âge	Adolescents et adultes	
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique	
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets. ↗	
Wikipédia	Ethambutol + isoniazid + rifampicin ↗	
DrugBank	Ethambutol ↗, Isoniazid ↗, Rifampicin ↗	

Résumé des preuves et recommandation du comité d'experts

The EMLc Subcommittee did not endorse the inclusion of this fixed-dose combination for the treatment of tuberculosis on the EMLc. The various fixed-dose combinations were considered as a group, as there is no clinical evidence for any of these combinations in children. However, it is difficult to determine the necessary appropriate combinations and what the strengths of the components should be in FDCs for use in children without examining further data (including pharmacokinetic data, stratified by weight and age). The Subcommittee therefore decided to endorse the lower strength rifampicin + isoniazid combinations (60 mg + 30 mg and 60 mg + 60 mg) and rifampicin + isoniazid + pyrazinamide (60 mg + 30 mg + 150 mg) as probably useful for many children, but requested an urgent review of all clinical evidence to support these and other potential combinations.

